Caris Life Sciences, Inc. (CAI) — Annual Report

Key Insights

• Caris Life Sciences, Inc. (CAI) reported a significant increase in revenue and gross profit in fiscal year 2025 compared to prior years, indicating strong growth in its core molecular profiling and pharma research and development services.
• The company has made notable investments in property, plant, and equipment, as well as in non-current assets, suggesting ongoing expansion and innovation efforts.
• Caris Life Sciences has a mix of current and non-current liabilities, including accrued liabilities, long-term debt, and other non-current liabilities, which will require close monitoring of the company's capital structure and liquidity position.